Viewing Study NCT02972034


Ignite Creation Date: 2025-12-25 @ 2:19 AM
Ignite Modification Date: 2026-03-02 @ 4:22 PM
Study NCT ID: NCT02972034
Status: TERMINATED
Last Update Posted: 2024-11-21
First Post: 2016-11-21
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Study of MK-8353 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Malignancies (MK-8353-013)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Organization Data

Organization:
Class: INDUSTRY
Study ID: 8353-013
Study Type: None
Study Domain: None
Study Link: None
Lead Sponsor:
Lead Sponsor Class: INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type: SPONSOR
Responsible Party Affiliation:
Old Name: None
Old Organization: None

Collaborators